JPRN-jRCT2080221952未知3 期
Open label multicenter study to assess the efficacy, safety, and tolerability of bosentan in Japanese patients with pulmonary arterial hypertension (PAH) in WHO functional class II.
Actelion Pharmaceuticals Japan Ltd.0 个研究点目标入组 16 人开始时间: 2012年10月26日最近更新:
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •* PAH idiopathic
- •* PAH familial
- •* PAH secondary to connective tissue or auto-immune diseases
- •* PAH secondary to atrial septum defect (ASD)<2 cm, ventricular septum defect (VSD) <1 cm or patent ductus arteriosus (PDA)
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)Subjects with known or suspected Coronary Artery Disease (CAD)EUCTR2012-002563-10-GBBayer AG426
进行中（未招募）
1 期
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)EUCTR2012-002563-10-DEBayer HealthCare AG450
进行中（未招募）
1 期
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)Subjects with known or suspected Coronary Artery Disease (CAD)EUCTR2012-002563-10-FRBayer HealthCare AG450
进行中（未招募）
不适用
An open label, multi-center study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura ITPEUCTR2004-000537-11-ITZLB BEHRING60
进行中（未招募）
不适用
An open-label, multicenter study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura (ITP)Immune thrombocytopenic purpura (ITP) is the most common autoimmune disease. It is a bleeding disorder characterized by decreased counts of circulating platelets and normal or increased numbers of megakaryocytes in the bone marrow.EUCTR2004-000537-11-DEZLB Behring AG60